Skip to content
Fiscal Receipts

Senate LDA lobbying filing

CENTENE CORPORATION

Registrant: CENTENE CORPORATION Year: 2024 Period: First Quarter Type: Q1

View on lda.senate.gov ↗

Reported income

not reported

Reported expenses

$1.41M

Tracked program mentions2

Quoted activity text is clipped to a short extract; each filing’s full description is under Lobbying activities below.

Lobbying activities3

  • Health IssuesHCR

    Issues related to the timeline and upcoming expiration of the Advance Premium Tax Credits (APTCs).

  • Medicare/MedicaidMMM

    H.R. 4822, Health Care Price Transparency Act of 2023, including provisions related to Improving Seniors Timely Access to Care Act concerning the modernization of the prior authorization process S. 3950, Delivering Unified Access to Lifesaving Services (DUALS) Act of 2024, including provisions requiring each state to select, develop and implement a comprehensive, integrated health plan for dual-eligible beneficiaries, and plans to develop and update care coordination plans, establish ombudsman offices, and establish a care coordinator for each beneficiary, reduce look-alike plans, create a single appeals process, and reduce third-party marketing organization incentives to target beneficiaries, expanding Program of All-Inclusive Care for the Elderly (PACE) coverage, and acknowledge dual eligibles are a diverse group with complex needs, including individuals with multiple chronic conditions, physical disabilities, mental illness, and cognitive impairments such as dementia and developmental disabilities. Issues related to Medicaid Redetermination unwinding process. Issues related to CMMI VBID (Value Based Insurance Design) application and criteria and new guidelines. Issues related to Pharmacy Benefit Management (PBM). Issues related to behavioral health. Issues related to prior authorization.

  • Taxation/Internal Revenue CodeTAX

    H.R. 7024, Tax Relief for American Families and Workers Act of 2024, including provisions that allow us to deduct innovation and amortization including deduction for research and experimental expenditures, and the extension of allowance for depreciation, amortization, or depletion in determining the limitation on business interest.

Lobbyists4

  • DANNY LY
  • JOHN KAELIN
  • PETER ECKRICH
  • SIMONE MYRIE

Source: U.S. Senate Lobbying Disclosure Act database. Dollar figures (underlined) cite the filing record on lda.senate.gov — click to view the citation. Amounts shown as “not reported” are absent from the filing itself.